Completed PHASE3 INTERVENTIONAL 2-arm NCT03463707

BP101 for Adults With Female Sexual Dysfunction

Multicenter, Double-blind, Randomized, Placebo-controlled Phase III Confirmatory Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire

Sponsor: Ivix LLX

Conditions Female Sexual Dysfunction Hypoactive Sexual Desire Disorder Sexual Desire Disorder

Interventions BP101 Placebo

Updated 8 times since 2018 Last updated: Feb 10, 2020 Started: Mar 5, 2018 Primary completion: Nov 26, 2018 Completion: Jan 23, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Female Sexual Dysfunction and Hypoactive Sexual Desire Disorder and is currently completed. Ivix LLX leads this study, which shows 8 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Mar 2020 — Jan 2021 [monthly]

Completed PHASE3

Status: Recruiting → Completed

▶ Show 3 earlier versions

Jun 2018 — Mar 2020 [monthly]

Recruiting PHASE3
Apr 2018 — Jun 2018 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Mar 2018 — Apr 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ivix LLX

Data source: Ivix LLX

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barnaul, Russia , Kazan', Russia , Krasnodar, Russia , Moscow, Russia , Nizhny Novgorod, Russia , Orenburg, Russia , Saint Petersburg, Russia , Samara, Russia , Saratov, Russia , Saratovskaya, Russia and 3 more locations